Journal of Hematology

Scope & Guideline

Innovating Insights into Blood Disorders

Introduction

Explore the comprehensive scope of Journal of Hematology through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Journal of Hematology in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1927-1212
PublisherELMER PRESS INC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJ HEMATOL / J. Hematol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address9225 LESLIE ST, STE 201, Ontario, RICHMOND HILL L4B 3H6, CANADA

Aims and Scopes

The Journal of Hematology focuses on advancing knowledge in the field of hematology through the dissemination of high-quality research articles. The journal aims to cover a wide range of hematological disorders, treatment modalities, and advancements in clinical practice, with a particular emphasis on innovative therapies and patient outcomes.
  1. Clinical Research in Hematological Malignancies:
    The journal publishes studies related to various hematological malignancies, including leukemia, lymphoma, and myeloma, focusing on clinical trials, treatment outcomes, and novel therapeutic strategies.
  2. Transfusion Medicine and Hemostasis:
    Research on blood transfusion practices, management of bleeding disorders, and the role of hemostatic agents is a core area, addressing both clinical and laboratory aspects.
  3. Genetics and Molecular Biology in Hematology:
    The journal emphasizes the genetic and molecular underpinnings of hematological diseases, including studies on mutations, genetic predispositions, and the role of biomarkers in diagnosis and treatment.
  4. Patient-Centered Outcomes and Quality of Life:
    An important aim is to evaluate the impact of hematological diseases and their treatments on patients' quality of life, including psychosocial factors and adherence to therapy.
  5. Innovative Therapeutics and Clinical Trials:
    The journal highlights cutting-edge therapeutic modalities, including CAR-T cell therapy, monoclonal antibodies, and gene therapies, along with the results of clinical trials and real-world studies.
  6. Epidemiology and Health Disparities:
    Research that explores the epidemiological aspects of hematological disorders, including disease prevalence, outcomes across different populations, and health disparities.
The Journal of Hematology has identified several emerging trends and themes that are gaining traction in recent years, reflecting the evolving landscape of hematology research and clinical practice.
  1. Immunotherapy and CAR-T Cell Therapies:
    There is a significant increase in publications focusing on immunotherapy, including CAR-T cell therapies for hematological malignancies, highlighting their rapid development and clinical application.
  2. Real-World Evidence and Patient Registries:
    An upward trend in studies utilizing real-world data and patient registries is evident, providing insights into treatment outcomes and effectiveness in diverse populations.
  3. Genomic and Molecular Profiling:
    Research focusing on the genomic and molecular characterization of hematological diseases is on the rise, emphasizing the importance of personalized medicine and targeted therapies.
  4. Management of COVID-19 in Hematology Patients:
    Emerging studies addressing the impact of COVID-19 on patients with hematological disorders, including vaccination responses and treatment adaptations, are increasingly prevalent.
  5. Health Disparities and Patient-Centered Care:
    There is a growing emphasis on understanding health disparities in hematology, with research focusing on social determinants of health and their impact on patient outcomes.
  6. Chronic Conditions and Comorbidities:
    An increasing focus on the management of chronic conditions and comorbidities among patients with hematological diseases is evident, particularly in the context of aging populations.

Declining or Waning

While the Journal of Hematology continues to explore a wide range of topics, certain areas of research have shown a declining trend in recent publications. This shift may reflect broader changes in the field or the emergence of new priorities.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in publications focusing solely on traditional chemotherapy regimens for hematological malignancies as newer targeted therapies and immunotherapies gain prominence.
  2. Basic Hematology Education:
    Research articles centered on basic hematology education and training have diminished, possibly due to a shift towards more advanced and specialized topics that incorporate new technologies and treatment modalities.
  3. Longitudinal Studies of Established Treatments:
    Fewer studies are being published that focus on long-term outcomes associated with established treatments, as the emphasis shifts towards innovative therapies and their immediate effects.
  4. Hematopathology Techniques:
    The publication of studies focused solely on traditional hematopathology techniques has decreased, reflecting a move towards molecular and genetic diagnostics that utilize advanced technologies.
  5. Single-Agent Therapies:
    Research specifically on single-agent therapies is declining in favor of studies on combination therapies and novel treatment strategies that show improved efficacy.

Similar Journals

Egyptian Journal of Haematology

Fostering Collaboration for a Healthier Tomorrow in Hematology
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Blood Research

Connecting Researchers to Revolutionize Blood Health
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

BLOOD

Empowering Research in Blood Disorders.
Publisher: AMER SOC HEMATOLOGYISSN: 0006-4971Frequency: 52 issues/year

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Indian Journal of Hematology and Blood Transfusion

Inspiring Progress in Blood Health Through Rigorous Research
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

BLOOD REVIEWS

Elevating knowledge in blood disorders and cancer care.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Clinical Lymphoma Myeloma & Leukemia

Advancing the Frontiers of Hematologic Research
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

ACTA HAEMATOLOGICA

Connecting Experts in Hematology for Global Impact
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

LEUKEMIA & LYMPHOMA

Transforming the landscape of cancer treatment and care.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

Turkish Journal of Hematology

Empowering the global hematology community through open access.
Publisher: GALENOS PUBL HOUSEISSN: 1300-7777Frequency: 4 issues/year

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

Hematology-American Society of Hematology Education Program

Cultivating Expertise in Blood Health
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.